Abzena
Watertown, MA
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Abzena
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Watertown, MA
- Modalities
- ADC, Bioconjugation, Biologics (mAb), HPAPI, Linker-Payload Synthesis, AOC, RDC, Aseptic Fill-Finish
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesADC, Bioconjugation, Biologics (mAb), HPAPI, Linker-Payload Synthesis, AOC, RDC, Aseptic Fill-Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (8 modalities)
Recent News 10 articles
Abzena Announces Major Investment in Bioconjugation and ADC Capabilities in Response to Increasing Industry Demand - PR Newswire
Pfizer bolsters North Carolina manufacturing footprint with Abzena plant purchase - Fierce Pharma
Abzena Appoints Dr Moncef Slaoui to Board - citybiz
Abzena expands biologic manufacturing site - Cleanroom Technology
Pfizer quits Duchenne gene therapy, lays off staff following study setback - biopharmadive.com
Matt Stober Appointed to the Board of GeminiBio - Business Wire
Pfizer Acquires Abzena’s Biologic Manufacturing Facility - TechTarget
CEO Spotlight: Matthew Stober - Contract Pharma
Abzena taps into ProteoNic’s viral vector tech - BioProcess International
Manufacturing roundup: Symbiosis, BioGrad, Abzena, Eschbach and more - European Pharmaceutical Review
Represent this organization? Contact us to verify or update this profile.